The Status of Parathyroid Hormone Secretion in Covid-19 Patients

December 9, 2020 updated by: Sabahattin Destek, Bezmialem Vakif University

The Status of Parathyroid Hormone Secretion and Its Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer in Hospitalized Covid-19 Patients

COVID-19 infection causes a hypersensitive immune reaction and widespread inflammation in various organs of the body, especially through cytokines in the lungs. This cytokine-mediated widespread inflammation can also affect the parathyroid glands, resulting in impaired parathyroid secretion.

Researchers evaluated the levels of parathyroid hormone, calcium, phosphorus, and alkaline phosphatase in patients hospitalized for COVID-19 infection. Researchers excluded patients on intensive care therapy and patients with known parathyroid disease.

The researchers examined the association of parathyroid hormone secretion with COVID-19 disease, white blood cells, neutrophil / lymphocyte ratio, C reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone level of healthy people without COVID-19 infection and known parathyroid disease with the parathyroid hormone level of Covid-19 patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The coronavirus-2 (SARS-COV-2) virus, which can cause severe acute respiratory syndrome through the droplet, has caused the global Coronavirus 19 (COVID-19) pandemic. COVID-19 infection can be asymptomatic or lead to serious illness and even death. This virus causes a hypersensitive immune reaction and varying degrees of widespread inflammation through cytokines in various organs of the body, mainly the lungs.

Cytokine-mediated widespread inflammation caused by the virus may also affect the parathyroid glands, causing their functions to deteriorate. Thus, it may cause changes in parathyroid hormone secretion.

The researchers evaluated the results of serum parathyroid hormone, calcium, phosphorus, alkaline phosphatase tests in patients who were symptomatic and hospitalized with COVID-19 infection. Participants also evaluated the relationship of parathormone with white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone levels of patients with COVID-19 infection with the parathyroid hormone levels of healthy individuals without COVID-19 infection and parathyroid disease. So the investigators looked for differences in parathyroid hormone levels between both groups. Researchers did not include patients in the intensive care unit and patients with known parathyroid disease.

Study Type

Observational

Enrollment (Actual)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey, 34093
        • Bezmialem VU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients who were hospitalized and treated for COVID-19 without parathyroid disease were formed.

Description

Inclusion Criteria:

  • To accept research.
  • Being over the age of 18.
  • COVID 19 test results to be positive.
  • Not taking parathyroid disease medication before.
  • Receiving inpatient treatment in the COVID service in the hospital.

Exclusion Criteria:

  • Not accepting research.
  • Be under the age of 18.
  • Negative COVID 19 test results for patients.
  • COVID patients treated as outpatient.
  • Parathyroid disease in the healthy control group.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Covid-19 Patient Group
10 ml of venous blood was taken from the forearm venous vein from people in the Covid-19 Patient Group, and the level of parathyroid hormone, calcium, phosphorus, alkaline phosphatase was measured from this blood.
Diagnostic test: Venous blood was collected for biochemistry testing
From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
Healthy Control Group
10 ml of venous blood will be taken from the forearm venous vein from the healthy control group and the parathyroid hormone, calcium, phosphorus, alkaline phosphatase level will be measured from this blood.
Diagnostic test: Venous blood was collected for biochemistry testing
From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
White blood cells (WBC) results of Covid 19 patient group
Time Frame: 90 days
In the study, serum WBC results were recorded in Covid 19 patient groups.
90 days
Neutrophil / lymphocyte ratio (N/LO) results of Covid 19 patient group
Time Frame: 90 days
In the study, serum N/LO results were recorded in Covid 19 patient groups.
90 days
C-reactive protein (CRP) results of Covid 19 patient group
Time Frame: 90 days
In the study, serum CRP results were recorded in Covid 19 patient groups.
90 days
Fibrinogen results of Covid 19 patient group
Time Frame: 90 days
In the study, serum fibrinogen results were recorded in Covid 19 patient groups.
90 days
Procalcitonin results of Covid 19 patient group
Time Frame: 90 days
In the study, serum procalcitonin results were recorded in Covid 19 patient groups.
90 days
Ferritin results of Covid 19 patient group
Time Frame: 90 days
In the study, serum ferritin results were recorded in Covid 19 patient groups.
90 days
D-dimer results of Covid 19 patient group
Time Frame: 90 days
In the study, serum D-dimer results were recorded in Covid 19 patient groups.
90 days
Comparison of parathyroid hormone between groups
Time Frame: 90 days
In the study, serum parathyroid hormone results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days
Comparison of calcium between groups
Time Frame: 90 days
In the study, serum calcium results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days
Comparison of phosphorus between groups
Time Frame: 90 days
In the study, serum phosphorus results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days
Comparison of alkaline phosphatase between groups
Time Frame: 90 days
In the study, serum alkaline phosphatase results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bezmialem Vakif University

Collaborators

Didem Ertorul

Investigators

  • Study Chair: Derya Özalp Çelikçi, Dr, Sancaktepe Education and Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 10, 2020

Primary Completion (Actual)

December 1, 2020

Study Completion (Actual)

December 9, 2020

Study Registration Dates

First Submitted

December 8, 2020

First Submitted That Met QC Criteria

December 9, 2020

First Posted (Actual)

December 10, 2020

Study Record Updates

Last Update Posted (Actual)

December 10, 2020

Last Update Submitted That Met QC Criteria

December 9, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 08122020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

The study will be shared when it becomes an article.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19 Infection

Clinical Trials on Venous blood was collected for biochemistry testing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe